Background: Large Tumor Suppressor 2(LATS2) gene is a putative tumor suppressor gene with potential roles in regulation of cell proliferation and apoptosis in lung cancer. The aim of this study is to explore the association of aberrant LATS2 expression with EGFR mutation and survival in lung adenocarcinoma(AD), and the effects of LATS2 silencing in both lung AD cell lines.
Introduction
LATS2 (Large Tumor Suppressor 2), one of the two human homologues of Drosophila warts, is a putative tumor suppressor gene which encodes for a serine/threonine kinase 1 . As a component in the Hippo signaling pathway, LATS2 kinase plays a critical role in controlling organ size development and in coordinating cell proliferation and apoptosis 2,3 . As a putative tumor suppressor gene, LATS2 displays multiple mechanisms of actions in different cancer cell types, including cell cycle regulation by controlling G1/S and G2/M transition 4, 5 , induction of apoptosis by down-regulating anti-apoptotic proteins Bcl-2 and Bcl-X L 6 , as well as maintenance of mitotic fidelity and genetic stability by interacting with other regulators of cell division, such as p53 7 and Aurora kinases [8] [9] [10] .
Dysregulation of LATS2 functions has been found in different types of tumors.
The chromosomal location of LATS2 is mapped to 13q11-q12 where there is frequent loss of heterozygosity 11 . In breast cancer, LATS2 mRNA expression was downregulated by promoter hypermethylation and this alteration was associated with large tumor size, high rate of metastasis and estrogen receptor and progesterone receptor negativity 12 . LATS2 may also play a role in the development of prostate cancer based on findings that reduced LATS2 expression occurred in prostate tumors and LATS2 negatively modulated androgen receptor-regulated gene transcription 13 . In malignant mesothelioma (MM), LATS2 was found to be inactivated in MM cells and this inactivation will lead to deregulated cell growth by allowing constitutive activation of M a n u s c r i p t 5 the downstream transcription factor of LATS2 in the Hippo pathway, YAP 14, 15 . The expression of LATS2 exhibits suppressive effects on mesothelioma cells.
In non-small cell lung cancer (NSCLC), occasional information has been reported on the effects of aberrant expression of LATS2 except its being one potential targets for microRNA-135b action to promote lung cancer metastasis 16 . LATS2
mutations are rare 17,18 but other mechanisms have been reported to cause downregulation of its expression such as promoter hypermethylation 19 and micro-RNA regulation 20, 21 . The relation between reduced LATS2 expression and lung cancer progression, and the underlying mechanisms remain unknown. In addition, we have previously found from expression profiling experiments that LATS2 showed differential expression between pulmonary adenocarcinomas with wild-type EGFR and ones bearing EGFR mutations at exons 18 to 21 22 . In this study, we further validated the differential expression of LATS2 in lung adenocarcinoma (AD) tissues in values to base of two of these relative expression levels were used in the following statistical analysis.
Immunohistochemistry
Immunohistochemistry(IHC) of the LATS2 protein was performed on formalin-fixed, paraffin-embedded sections of an independent set of 79 paraffin blocks of lung AD different from those used for real-time PCR assay above. was obtained by multiplying the intensity (1-3) and reactivity extension (0-100) for each case. Mean score was taken for the whole group of samples and samples with H scores above mean would be classified as of higher expression levels whereas those with H scores below mean would be classified as of lower expression levels.
Western Blotting
Whole-cell lysates were prepared in 1X RIPA lysis buffer (Rockland) with addition of 1% protease inhibitor cocktail (Sigma). Total protein (80 ug for Akt and 50 ug for other proteins) was fractionated using SDS-PAGE and then transferred to nitrocellulose membranes (ExPro). After blocking with 5% non-fat milk in Tris buffered saline, membranes were incubated overnight at 4°C with various primary antibodies and then probed with HRP-conjugated secondary antibodies (anti-rabbit or anti-mouse, Abcam) for 2 hours at 4°C. Primary antibodies to LATS2, ERK 1/2, p-M a n u s c r i p t 10 ERK1/2, Akt, p-Akt (T308), p-Akt (S473) and p53 were from Cell Signaling. β-actin (Sigma) was used as a loading control. Immune complexes were visualized by using ECL detection kit (GE Healthcare, Japan), and the band intensity was quantified by Image J software.
LATS2 siRNA Transfection
Cells were transfected using the Hiperfect reagent according to the manufacturer's instructions (Qiagen, UK). The target sequence of LATS2 specific siRNA (siLATS2) is 5'-CTCCGCAAAGGGTACACTCAA-3', and 5nM siRNA was added to silence LATS2. One negative control siRNA (Qiagen, UK) was also included.
Cultured cells were harvested for RNA or protein extraction at baseline and at 48 hours.
Statistical Analysis
Data were analyzed with SPSS 18.0 software. Differences between groups were estimated using the Chi-squared test, the Student's t test, or the log-rank test.
Disease-free survival (DFS) and overall survival (OS) curves were calculated by the Kaplan-Meier method. Stepwise multiple regression models were built to determine the clinical parameters that independently predict either PFS or OS. Log rank tests were used to compare cumulative survival between different groups. All p values were two-sided and p < 0.05 was considered statistically significant. Cox proportional M a n u s c r i p t 11 regression model was applied for multivariate analysis. A probability level of 0.05 was used to determine statistical significance.
Results

Demographics of lung cancer patients
Fifty patients were recruited prospectively before they underwent surgical resection, with 23 (46.9%) male and 26 (53.1%) female patients and with age range of 38 to 88 years (mean ± S.D.; 64.1±9.2 years). The ratio of non-smokers (61%) to exor current smokers (39%) was around 2 to 1. 28 tumors were EGFR wild-type (57%) with no mutation at exons 18 -21 while 21 were EGFR mutants that showed at least one EGFR mutation in exons 18 to 21 (43%). The details can be found in Table 1 .
LATS2 mRNA Expression in lung AD patients
AD tissue samples expressing LATS2 mRNA at levels above the mean expression level(6.3; range 0-13.1) were assigned to the high expression group(mean expression value 9.4, n=23), and samples with expression less than the mean value were considered as the low expression group(mean expression value 3.6, n=26).
LATS2 mRNA levels showed no significant differences between different clinical parameters, including gender, age, smoking history, pathological stage and EGFR mutation status (Table 1 ). Survival analysis indicated that high LATS2 M a n u s c r i p t 12 expression group had significantly longer disease-free survival (DFS) (p=0.002, Figure 1A ) and overall survival (OS) (p=0.041, Figure 1B) p=0.006) were also significant prognostic factor of DFS (Table 2) . When dividing samples based on both EGFR mutation status and LATS2 level, patients with wildtype EGFR as well as expressing low LATS2 expression displayed poor DFS ( Figure   1C ). Inferior DFS was also observed in non-smokers exhibiting low LATS2 levels ( Figure 1D ).
LATS2 protein expression in lung AD tumors
Immunohistochemistry (IHC) staining on the independent set of 79 paraffin blocks of AD indicated that LATS2 protein was expressed at relatively low levels in both the cytoplasm and the nucleus( Figure 2C A c c e p t e d M a n u s c r i p t 13 low levels of LATS2 cytoplasm expression(p=0.031). In males, EGFR wild-type cohort expressed slightly higher cytoplasmic staining of LATS2. These observations with LATS2 IHC were consistent with the findings of LATS2 expression at mRNA levels among gender with EGFR mutation status groups in a different set of tumor specimens with real-time PCR assay done as described in the previous section.
Nuclear LATS2 expression levels were generally low and no remarkable difference was found between all the clinical parameters examined.
LATS2 mRNA expression in AD cell lines
Before transfection, LATS2 protein levels were quantified in each cell line ( Figure   2A ). Basal LATS2 expression in H2023, HKULC-2 and H1650 were much higher, while H1648, HKULC-4, H1975 and PC9 exhibited relatively lower expression levels of LATS2. After being transfected with LATS2-specific siRNA (siLATS2) or Negative
Control siRNA (siCont), LATS2 expression was successfully silenced in all cell lines confirmed with reduced levels of LATS2 protein ( Figure 2B ).
LATS2 modulates ERK pathway in the EGFR wild-type AD cell lines with high
LATS2 expression
After successfully silencing LATS2 expression in AD cell lines, we first examined for changes in phosphorylation of mitogen-activated protein kinase, ERK1/2 ( Figure 3A) .
In most of the AD cell lines studied except for H1975 in which we failed to detect the activation of ERK1/2, the levels of phosphorylated ERK1/2 did not alter significantly Phosphorylation at Ser473, which contributes to maximal Akt Activity, was also improved by LATS2 knockdown in HKULC-2 cells ( Figure 3C ). Together with above results, LATS2 might diminish Akt activation in H2023 and HKULC-2 cells.
Both cell lines showed high LATS2 expression at baseline. In H1650, the addition of LATS2 siRNA slightly reduced the level of phosphorylated Akt at Ser473. Although the difference was not significant, it was still plausible that LATS2 may differentially influence Akt activation and the regulation might be independent of EGFR mutation status.
M a n u s c r i p t 15
Silencing of LATS2 induces p53 accumulation in lung AD cell lines with low basal p53 levels
Previous reports have indicated that LATS2 is able to stabilize p53 thus facilitating p53-dependent checkpoint response to mitotic stress in breast cancer and osteosarcoma cells ely. However, in HKULC-2 cells, LATS2 knockdown markedly increased total p53 levels ( Figure 3D ), suggesting that, instead of inducing p53 accumulation, LATS2 may actually downregulate p53 protein expression in these cells.
Noticeably, HKULC-2 cells expressed very low amount of p53 at baseline ( Figure   3D ). Another two cell lines, HKULC-4 and H1650, which also exhibited low basal p53 expression, LATS2 silencing likewise enhanced p53 levels although the differences were not statistically significant.
Discussion
In this study, we demonstrated that low LATS2 expression was an independent and significant predictor of poor overall survival. Furthermore, expression of LATS2 correlated with DFS of these lung adenocarcinoma patients (partial correlation ratio, 0.37; p= 0.012). These findings suggested that LATS2 may express tumor suppressive effects in lung adenocarcinoma. Since wild type EGFR also significantly predicted inferior DFS, it is not surprising that tumors with wild type EGFR and low LATS2 expression exhibited the shortest DFS (overall p=0.004, Figure 1C ). In non-smokers, in which EGFR mutations are more common, significant difference in DFS was still observed between two LATS2 expression groups (p = 0.010, Figure 1D ). Similar observation has been made before, that knockdown of YAP (Yes kinase-associated protein), whose functions can be inhibited by LATS2, sensitizes cancer cells to EGFR-TKI erlotinib 33 . Further studies are warranted to investigate the relationships between LATS2 expression levels and therapeutic responses of these patients. In this study, LATS2 may suppress p53 expression, which is contradictory to previous studies that LATS2 can cause p53 induction in response to mitotic apparatus damage 7 as well as oncogenic activation 51 . That may be partially explained by the absence of mitotic or oncogenic stress introduced to cells in this study. On the other hand, in NSCLC tumors, downregulated LATS2 mRNA levels have been found to be and Snail, to disclose the comprehensive interaction between LATS2 and p53 in lung adenocarcinoma cells. Moreover, since silencing of LATS2 would induce p53 accumulation, we might postulate that LATS2 is linked to drug sensitivity through regulation of p53-mediated processes 54 .
In conclusion, relatively higher level of LATS2 gene correlates with the better survival in patients with early stage resected lung AD. In vitro LATS2 knockdown suggested that this differential expression could impact EGFR-activated signaling network, particularly in high LATS2 expression group, and p53 pathway. LATS2 also appeared to modulate different signaling pathways via phosphorylated ERK or Akt in A c c e p t e d M a n u s c r i p t M a n u s c r i p t p = 0.031 C (Con't) Group 1 = Tumors of EGFR mutant females (n=21) Group 2 = Tumors other than EGFR mutant females (n=38)
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